Joel Greenblatt’s Rigel Pharmaceuticals RIGL Stock Holding History

Joel Greenblatt’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,805	Closed	-$206K	–	1843
2025 Q4	$206K	Buy	+4,805	New	+$181K	﹤0.01%	1647

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's RIGL Position: Q1 2026 in Review

Joel Greenblatt sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 4,805 shares — an estimated $206K sold.

Joel Greenblatt first reported a position in RIGL in Q4 2025 and held it in 1 quarter. The position peaked at $206K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

Joel Greenblatt reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Joel Greenblatt sold 4,805 Rigel Pharmaceuticals shares in Q1 2026, an estimated $206K.
Joel Greenblatt first reported a position in Rigel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Joel Greenblatt's Rigel Pharmaceuticals position peaked at $206K in Q4 2025.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.